US4782059A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of controlling mycotic infections and compositions therefor
Assignee: Merck and Co Inc
•
Filing: 1986-09-29
•
Granted: 1988-11-01
•
Expires: 2006-09-29
Abstract
Abstract Certain fungistats when employed in combination have been found to exhibit synergistic antifungal properties and further exhibit fungicidal properties.
Inventors
- 👤 Hans H. Gadebusch
- 👤 Mary E. Valiant
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 21:11
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
94 words
A method for treating subjects with mycotic infecions comprising directing to the site where control is desired by administering a fungicidally effective amount of: (1) a compound having 14α-methyldemethylase inhibitor activity and named cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]piperazine(ketoconazole); and (2) a compound having squalene epoxidase inhibitor activity and named N-methyl-N-(3-phenylpropenyl)-1-naphthalenemethamine hydrochloride (naftifine); wherein the compound having 14α-methyldemethylase inhibitor activity is employed in an amount of from about 2.85 to 4.75 mg/kg of body weight, and wherein the compound having squalene epoxidase inhibitor activity is employed in an amount of from about 2.85 to 4.75 mg/kg of body weight.
Claim 2
Independent Claim
94 words
A method for treating subjects with mycotic infecions comprising directing to the site where control is desired by administering a fungicidally effective amount of: (1) a compound having 14α-methyldemethylase inhibitor activity and named cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]piperazine(ketoconazole); and (2) a compound having squalene epoxidase inhibitor activity and named N-methyl-N-(3-phenylpropenyl)-1-naphthalenemethamine hydrochloride (naftifine); wherein the compound having 14α-methyldemethylase inhibitor activity is employed in an amount of from about 2.85 to 4.75 mg/kg of body weight, and wherein the compound having squalene epoxidase inhibitor activity is employed in an amount of from about 2.85 to 4.75 mg/kg of body weight.
Claim 3
Dependent Claim
13 words
A method according to claim 1 wherein the treatment is by parenteral administration.
Claim 4
Dependent Claim
13 words
A method according to claim 1 wherein the treatment is by oral administration.
Claim 5
Dependent Claim
68 words
An oral pharmaceutical composition suitable for treating mycotic infections in unit dosage form comprising per dosage unit of: (1) from about 200 to 400 milligrams of a compound having 14α-methyldemethylase inhibitor activity and named cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]-phenyl]piperazine (ketoconazole); and (2) from about 200 to 400 milligrams of a compound having squalene epoxidase inhibitor activity and named N-methyl-N-(3-phenylpropenyl-1-naphthalenemethamine hydrochloride (naftifine); wherein said compounds are in admixture with a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
68 words
An oral pharmaceutical composition suitable for treating mycotic infections in unit dosage form comprising per dosage unit of: (1) from about 200 to 400 milligrams of a compound having 14α-methyldemethylase inhibitor activity and named cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]-phenyl]piperazine (ketoconazole); and (2) from about 200 to 400 milligrams of a compound having squalene epoxidase inhibitor activity and named N-methyl-N-(3-phenylpropenyl-1-naphthalenemethamine hydrochloride (naftifine); wherein said compounds are in admixture with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
15 words
A composition according to claim 4 in which the unit dosage form is a tablet.
Claim 8
Dependent Claim
15 words
A composition according to claim 4 in which the unit dosage form is a capsule.
Claim 9
Dependent Claim
66 words
A parenteral pharmaceutical composition suitable for treating mycotic infection in unit dosage form: comprising per dosage unit of: from about 200 to 400 milligrams of a compound having 14α-methyldemethylase inhibitor activity and named cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-ylmethyl)-1,3-dioxolan-4-yl] -methoxy]phenyl]piperazine (ketoconazole); and from about 200 to 400 milligrams of a compound having squalene epoxidase inhibitor activity and named N-methyl-N-(3-phenylpropenyl)-1-naphthalenemethamine hydrochloride (naftifine); wherein said compounds are in admixture in aqueous parenteral compositions.
Claim 10
Dependent Claim
66 words
A parenteral pharmaceutical composition suitable for treating mycotic infection in unit dosage form: comprising per dosage unit of: from about 200 to 400 milligrams of a compound having 14α-methyldemethylase inhibitor activity and named cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-ylmethyl)-1,3-dioxolan-4-yl] -methoxy]phenyl]piperazine (ketoconazole); and from about 200 to 400 milligrams of a compound having squalene epoxidase inhibitor activity and named N-methyl-N-(3-phenylpropenyl)-1-naphthalenemethamine hydrochloride (naftifine); wherein said compounds are in admixture in aqueous parenteral compositions.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-01 | 1992-05-02 | 1992-11-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-01 | 1996-05-02 | 1996-11-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-01 | 2000-05-02 | 2000-11-01 | $7700.00 | Window Closed / Lapsed |